Add to ORKG[[sponsorship]]生物化學研究所[[note]]出版中(accepted);[SCI];有審查制度;具代表性[[note]]http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=Drexel&SrcApp=hagerty_opac&KeyRecord=0950-9232&DestApp=JCR&RQ=IF_CAT_BOXPLO
BACKGROUND: Pancreatic cancer (PC) harbours an activated point mutation (Kras(G12D)) in the Kras pro...
Pancreatic ductal adenocarcinoma (PDA) is a devastating malignancy with limited and modest clinical ...
Pancreatic ductal adenocarcinoma (PDAC) remains highly refractory to treatment. While th
KRAS is one of the most mutated genes in human cancer. Its crucial role in the tumourigenesis of pan...
Pancreatic ductal adenocarcinoma (PDA), the fourth leading cause of cancer death in the U.S., is a d...
BACKGROUND & AIMS: Development of pancreatic ductal adenocarcinoma (PDAC) involves activation of c-K...
Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is rarel...
Hedgehog (Hh) signaling is deregulated in multiple human cancers including pancreatic ductal adenoca...
Pancreatic cancer is a lethal disease that is almost invariably associated with a KRAS gene mutation...
Pancreatic cancer is currently the fourth most common cancer, is increasing in incidence and soon wi...
Oncogenic Kras is increasingly appreciated as an instigator of an inflammatory program that facilita...
Activating mutations in KRAS are the hallmark genetic alterations in pancreatic ductal adenocarcinom...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2016.Cataloged from PD...
Pancreatic cancer is currently the fourth most common cancer, is increasing in incidence and soon wi...
Pancreatic ductal adenocarcinoma (PDAC) remains highly refractory to treatment. While the KRAS oncog...
BACKGROUND: Pancreatic cancer (PC) harbours an activated point mutation (Kras(G12D)) in the Kras pro...
Pancreatic ductal adenocarcinoma (PDA) is a devastating malignancy with limited and modest clinical ...
Pancreatic ductal adenocarcinoma (PDAC) remains highly refractory to treatment. While th
KRAS is one of the most mutated genes in human cancer. Its crucial role in the tumourigenesis of pan...
Pancreatic ductal adenocarcinoma (PDA), the fourth leading cause of cancer death in the U.S., is a d...
BACKGROUND & AIMS: Development of pancreatic ductal adenocarcinoma (PDAC) involves activation of c-K...
Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is rarel...
Hedgehog (Hh) signaling is deregulated in multiple human cancers including pancreatic ductal adenoca...
Pancreatic cancer is a lethal disease that is almost invariably associated with a KRAS gene mutation...
Pancreatic cancer is currently the fourth most common cancer, is increasing in incidence and soon wi...
Oncogenic Kras is increasingly appreciated as an instigator of an inflammatory program that facilita...
Activating mutations in KRAS are the hallmark genetic alterations in pancreatic ductal adenocarcinom...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2016.Cataloged from PD...
Pancreatic cancer is currently the fourth most common cancer, is increasing in incidence and soon wi...
Pancreatic ductal adenocarcinoma (PDAC) remains highly refractory to treatment. While the KRAS oncog...
BACKGROUND: Pancreatic cancer (PC) harbours an activated point mutation (Kras(G12D)) in the Kras pro...
Pancreatic ductal adenocarcinoma (PDA) is a devastating malignancy with limited and modest clinical ...
Pancreatic ductal adenocarcinoma (PDAC) remains highly refractory to treatment. While th